325 related articles for article (PubMed ID: 11175283)
1. Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions.
Gómez-Garre P; Sanz Y; Rodríguez De Córdoba SR; Serratosa JM
Eur J Hum Genet; 2000 Dec; 8(12):946-54. PubMed ID: 11175283
[TBL] [Abstract][Full Text] [Related]
2. Mutation screening for Japanese Lafora's disease patients: identification of novel sequence variants in the coding and upstream regulatory regions of EPM2A gene.
Ganesh S; Shoda K; Amano K; Uchiyama A; Kumada S; Moriyama N; Hirose S; Yamakawa K
Mol Cell Probes; 2001 Oct; 15(5):281-9. PubMed ID: 11735300
[TBL] [Abstract][Full Text] [Related]
3. Two novel mutations in the EPM2A gene in a Korean patient with Lafora's progressive myoclonus epilepsy.
Ki CS; Kong SY; Seo DW; Hong SB; Kim HJ; Kim JW
J Hum Genet; 2003; 48(1):51-4. PubMed ID: 12560877
[TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of mouse homologue for the human epilepsy gene, EPM2A.
Ganesh S; Amano K; Delgado-Escueta AV; Yamakawa K
Biochem Biophys Res Commun; 1999 Apr; 257(1):24-8. PubMed ID: 10092504
[TBL] [Abstract][Full Text] [Related]
5. Novel human pathological mutations. Gene symbol: EPM2A. Disease: Lafora progressive myoclonus epilepsy.
Trujillo-Tiebas MJ; Fenollar-Cortés M; Gómez-Garré P; Lorda-Sánchez I; Serratosa JM; Ayuso García C
Hum Genet; 2007 Jun; 121(5):651. PubMed ID: 17879451
[No Abstract] [Full Text] [Related]
6. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy.
Minassian BA; Lee JR; Herbrick JA; Huizenga J; Soder S; Mungall AJ; Dunham I; Gardner R; Fong CY; Carpenter S; Jardim L; Satishchandra P; Andermann E; Snead OC; Lopes-Cendes I; Tsui LC; Delgado-Escueta AV; Rouleau GA; Scherer SW
Nat Genet; 1998 Oct; 20(2):171-4. PubMed ID: 9771710
[TBL] [Abstract][Full Text] [Related]
7. [Lafora disease. A new case of confirmation of diagnosis on molecular genetic studies].
Martínez-Bermejo A; López-Martín V; Serratosa JM; Gutiérrez-Molina M; Gómez-Garre P; Arcas J; Tendero A; Roche C; Pérez-Mies B
Rev Neurol; 2002 Jan 16-31; 34(2):117-20. PubMed ID: 11988905
[TBL] [Abstract][Full Text] [Related]
8. The Lafora disease gene product laforin interacts with HIRIP5, a phylogenetically conserved protein containing a NifU-like domain.
Ganesh S; Tsurutani N; Suzuki T; Ueda K; Agarwala KL; Osada H; Delgado-Escueta AV; Yamakawa K
Hum Mol Genet; 2003 Sep; 12(18):2359-68. PubMed ID: 12915448
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of laforin, a dual-specificity protein phosphatase implicated in Lafora disease.
Girard JM; Lê KH; Lederer F
Biochimie; 2006 Dec; 88(12):1961-71. PubMed ID: 17010495
[TBL] [Abstract][Full Text] [Related]
10. Regional and developmental expression of Epm2a gene and its evolutionary conservation.
Ganesh S; Agarwala KL; Amano K; Suzuki T; Delgado-Escueta AV; Yamakawa K
Biochem Biophys Res Commun; 2001 May; 283(5):1046-53. PubMed ID: 11355878
[TBL] [Abstract][Full Text] [Related]
11. Alport syndrome. Molecular genetic aspects.
Hertz JM
Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
[TBL] [Abstract][Full Text] [Related]
12. [Molecular genetics of epilepsy].
Yamakawa K
Rinsho Shinkeigaku; 2004 Nov; 44(11):858-60. PubMed ID: 15651314
[TBL] [Abstract][Full Text] [Related]
13. Identification of new and common mutations in the EPM2A gene in Lafora disease.
Minassian BA; Ianzano L; Delgado-Escueta AV; Scherer SW
Neurology; 2000 Jan; 54(2):488-90. PubMed ID: 10668720
[TBL] [Abstract][Full Text] [Related]
14. A novel exon 3 mutation in a Tunisian patient with Lafora's disease.
Khiari HM; Lesca G; Malafosse A; Mrabet A
J Neurol Sci; 2011 May; 304(1-2):136-7. PubMed ID: 21371719
[TBL] [Abstract][Full Text] [Related]
15. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes.
Ganesh S; Agarwala KL; Ueda K; Akagi T; Shoda K; Usui T; Hashikawa T; Osada H; Delgado-Escueta AV; Yamakawa K
Hum Mol Genet; 2000 Sep; 9(15):2251-61. PubMed ID: 11001928
[TBL] [Abstract][Full Text] [Related]
16. Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Ganesh S; Delgado-Escueta AV; Suzuki T; Francheschetti S; Riggio C; Avanzini G; Rabinowicz A; Bohlega S; Bailey J; Alonso ME; Rasmussen A; Thomson AE; Ochoa A; Prado AJ; Medina MT; Yamakawa K
Hum Mol Genet; 2002 May; 11(11):1263-71. PubMed ID: 12019207
[TBL] [Abstract][Full Text] [Related]
17. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation.
Fernández-Sánchez ME; Criado-García O; Heath KE; García-Fojeda B; Medraño-Fernández I; Gomez-Garre P; Sanz P; Serratosa JM; Rodríguez de Córdoba S
Hum Mol Genet; 2003 Dec; 12(23):3161-71. PubMed ID: 14532330
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional profiling of a mouse model for Lafora disease reveals dysregulation of genes involved in the expression and modification of proteins.
Ganesh S; Tsurutani N; Amano K; Mittal S; Uchikawa C; Delgado-Escueta AV; Yamakawa K
Neurosci Lett; 2005 Oct; 387(2):62-7. PubMed ID: 16084644
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the NHLRC1 gene are the common cause for Lafora disease in the Japanese population.
Singh S; Suzuki T; Uchiyama A; Kumada S; Moriyama N; Hirose S; Takahashi Y; Sugie H; Mizoguchi K; Inoue Y; Kimura K; Sawaishi Y; Yamakawa K; Ganesh S
J Hum Genet; 2005; 50(7):347-352. PubMed ID: 16021330
[TBL] [Abstract][Full Text] [Related]
20. Hepatic disease as the first manifestation of progressive myoclonus epilepsy of Lafora.
Gómez-Garre P; Gutiérrez-Delicado E; Gómez-Abad C; Morales-Corraliza J; Villanueva VE; Rodríguez de Córdoba S; Larrauri J; Gutiérrez M; Berciano J; Serratosa JM
Neurology; 2007 Apr; 68(17):1369-73. PubMed ID: 17452581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
